Eli Lilly and Company ($LLY) Stock Forecast: Down 5.2% Today

What is Eli Lilly and Company?

A pharmaceutical company with a focus on innovative drugs in various therapeutic areas, including oncology and Alzheimer's disease, saw volatility in the pharmaceutical stock market due to different factors.

Why is Eli Lilly and Company going down?

LLY stock is down 5.2% on Jul 29, 2025 19:51

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

LLY Price Chart

LLY Technical Analysis

LLY News

What's Going On With Eli Lilly Stock On Tuesday? - Eli Lilly ( NYSE:LLY )

Novo Nordisk cut its 2025 sales growth outlook to 8-14%, down from 13-21%, due to slow GLP-1 uptake. Eli Lilly's Jaypirca met the primary endpoint in a head-to-head CLL trial against J&J's Imbruvica. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/news/health-care/25/07/46698418/whats-going-on-with-eli-lilly-stock-on-tuesday-3

Eli Lilly Options Trading: A Deep Dive into Market Sentiment - Eli Lilly ( NYSE:LLY )

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/25/07/46689551/eli-lilly-options-trading-a-deep-dive-into-market-sentiment

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY )

Over 80 lawmakers urge FDA to act against illegal GLP-1 drug imports, citing safety risks. Counterfeit drugs smuggled from China include unapproved Ozempic, Wegovy versions. The market's back, and these 3 income stocks are thriving. See them here→ In a letter to the U.S.

https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel - Eli Lilly ( NYSE:LLY )

CHMP recommends Lilly's donanemab for early Alzheimer's in ApoE4 heterozygotes or non-carriers. TRAILBLAZER-ALZ trials show donanemab slowed cognitive decline and reduced disease progression risk. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On

https://www.benzinga.com/news/health-care/25/07/46629899/eli-lillys-early-alzheimers-drug-recommended-for-approval-by-european-drug-regulators-panel

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

https://www.zacks.com/stock/news/2612614/how-will-eli-lillys-oncology-drugs-perform-in-q2-earnings

Trending Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 5.0% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 5.2% Today

Huntington Ingalls Industries Inc. ($HII) Stock Forecast: Up 8.5% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Up 5.2% Today

lululemon athletica inc. ($LULU) Stock Forecast: Down 5.1% Today

Carvana Co ($CVNA) Stock Forecast: Up 15.9% Today

Roblox Corp ($RBLX) Stock Forecast: Up 11.3% Today

Southern Company (The) ($SO) Stock Forecast: Down 1.5% Today

Academy Sports and Outdoors, Inc. ($ASO) Stock Forecast: Down 5.1% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.1% Today

Eli Lilly and Company Price History

17.03.2025 - LLY Stock was up 15.4%

• Eli Lilly's stock soared after its oral GLP-1 drug, Orforglipron, successfully met Phase 3 goals in a diabetes trial, showing promising results in reducing A1C levels and weight in patients.
• Analysts are optimistic about the global potential of Orforglipron, with sales forecasts exceeding consensus estimates, leading to increased investor confidence in Eli Lilly's future prospects.
• The launch of Eli Lilly's weight-loss drug, Mounjaro, in India has triggered a craze in the market, showcasing the company's ability to innovate and capture consumer interest in new products.
• The positive news surrounding Eli Lilly's drug developments contrasts with Pfizer's decision to halt obesity pill development due to safety concerns, further highlighting the importance of successful clinical trials in the pharmaceutical industry.

01.04.2025 - LLY Stock was down 10.2%

• In spite of the strong upward momentum witnessed over the previous month and year, Eli Lilly (LLY) encountered a downward movement in its stock price today.
• This shift can be linked to the company falling short of Q1 earnings expectations, with a -5.11% surprise in earnings and a 0.86% miss in revenue.
• Moreover, the reduction in projected 2025 profit due to IPR&D-related expenses may have influenced investor sentiment, contributing to today's decline in the stock price.
• Investors are advised to keep a close watch on upcoming earnings releases and updates regarding the company's profitability forecast to assess the potential recovery of the stock from the current bearish trend.

01.04.2025 - LLY Stock was down 6.1%

• Despite a positive earnings forecast for the first quarter, Eli Lilly (LLY) saw a significant bearish movement.
• Some market influencers in LLY options trading displayed a bearish sentiment, potentially impacting the stock's downward trajectory.
• Ongoing legal proceedings involving Eli Lilly and Johnson & Johnson regarding alleged health risks associated with their products may have raised investor apprehensions, contributing to the bearish market sentiment.
• Concerns regarding the lawsuit's potential repercussions on Eli Lilly's financial performance and image could be prompting investors to offload the stock.

01.04.2025 - LLY Stock was down 10.7%

• A mix of results was reported by Eli Lilly for Q1, with earnings falling short of estimates while sales surpassed expectations, fueled by strong showings from Mounjaro and Zepbound.
• Despite a 45% increase in Q1 revenue and notable sales performance for key products, the stock saw a decrease, potentially linked to the revised 2025 profit projection tied to substantial IPR&D expenses.
• The market response to Eli Lilly's Q1 results may be connected to the disparity in earnings and revenue surprises, prompting scrutiny from investors about the company's future growth potential.
• Technical analysis pointed towards a bullish trajectory for Eli Lilly's stock; however, investor focus on the profit outlook and potential impact of IPR&D charges from the earnings report led to a bearish market response.

29.06.2025 - LLY Stock was down 5.2%

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

29.06.2025 - LLY Stock was down 6.1%

• The decline in Eli Lilly's stock could be linked to investors taking a bearish stance in options trading, as shown by publicly available options history.
• Concerns raised by Congress about the illegal import of weight-loss drugs from China, which also mentioned Eli Lilly, may have further dampened investor sentiment.
• While Eli Lilly received positive news of early Alzheimer's drug approval recommendation in Europe, the market seemed more influenced by general pessimism and regulatory risks.
• The conclusion of the Verve tender offer involving Eli Lilly likely impacted investor sentiment and contributed to the stock's bearish movement.

29.06.2025 - LLY Stock was down 6.7%

• The bearish movement in LLY stock could be attributed to concerns raised by Congress over illegal weight-loss drug imports from China, which might impact the company's reputation and sales.
• Despite the positive news of Eli Lilly's early Alzheimer's drug recommendation for approval in Europe, the market might be reacting more to the potential safety risks associated with illegal drug imports.
• Investors might be cautious about the upcoming Q2 earnings report, especially regarding the performance of Eli Lilly's oncology drugs, as any underperformance could have contributed to the bearish trend.
• The expiration of the Verve tender offer might also be a factor in the stock's movement, signaling potential shifts in the company's strategic partnerships or future developments.

15.06.2025 - LLY Stock was down 1.2%

• Deep-pocketed investors have recently taken a bearish approach towards Eli Lilly (LLY) options, which may have contributed to the stock's significant decline today.
• Despite the positive outlook for LLY's drugs like Mounjaro and Zepbound driving strong revenues, the bearish sentiment from market whales on the options front seems to have overshadowed the company's potential.
• The threat of 200% tariffs on pharmaceutical imports by President Trump could have also added to the overall bearish sentiment in the market, impacting stocks like Eli Lilly.
• While there were some bullish bets on Eli Lilly from other investors, the overall market movement today seems to have been influenced more by the bearish stance taken by market whales and external factors like trade tariffs.

16.04.2025 - LLY Stock was up 5.2%

• A recent 17% decline in LLY stock since Q1 results might have created a buying opportunity for investors seeking to benefit from the decrease.
• Despite concerns regarding its expensive valuation and declining estimates, the company's robust growth prospects are prompting investors to retain LLY stock.
• The bullish movement may be linked to investors reassessing Eli Lilly and Company's long-term potential, resulting in increased buying interest and driving up the stock price.

08.06.2025 - LLY Stock was up 0.2%

• Eli Lilly has showcased impressive performance, outperforming the market substantially over the past decade, attracting investors seeking strong returns.
• Sales growth fueled by non-obesity drugs like Verzenio and Taltz highlights the company's diversified product portfolio and its ability to seize market opportunities across different drug categories.
• Positive sentiments from Wall Street analysts, with most recommending buying the stock, might have bolstered investor confidence in the company's future, contributing to the stock's bullish movement.
• Eli Lilly's robust market performance, promising sales growth, and favorable analyst outlook likely supported the bullish stock movement observed today.

06.04.2025 - LLY Stock was down 5.2%

• Cutting Eli Lilly's price target to $883 due to PBM-related uncertainty after CVS dropped Zepbound may have caused a lack of investor confidence, contributing to the bearish movement.
• Despite bullish options activity on Eli Lilly, concerns over the setback with CVS and missed earnings in Q1 might have overshadowed the positive sentiment.
• Mixed reactions from analysts and the market's response to the earnings miss despite strong revenue growth suggest investors are cautious about the company's future performance.
• The reduction in 2025 profit outlook, not due to tariffs but IPR&D charges, could have added to the negative sentiment surrounding Eli Lilly, leading to the bearish market movement.

17.06.2025 - LLY Stock was down 3.4%

• Eli Lilly's stock (LLY) faced a bearish trend, potentially influenced by concerns regarding its valuation despite a strong performance in the last decade.
• The negative stance taken by significant investors towards LLY options could have contributed to the stock's downward pressure.
• Even though drugs like Mounjaro and Zepbound hold promise for driving robust quarterly earnings, the prevailing market sentiment towards Eli Lilly was mostly unfavorable, resulting in the bearish movement.